Valuation: ARPIDA

Market Cap 16.37M 19.87M 17.8M 14.83M 27.73M 1.89B 28.25M 195M 78.37M 993M 74.58M 72.99M 3.13B P/E 2024
6.22x
P/E 2025 -8.95x
Enterprise Value 10.46M 12.7M 11.38M 9.48M 17.72M 1.21B 18.06M 125M 50.1M 634M 47.67M 46.66M 2B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
62.03%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Investor Relations Contact 59 -
Director TitleAgeSince
Director/Board Member - 27/03/2025
Chairman - 27/03/2025
Change 5-day change 1-year change 3-year change Capi.($)
-0.62%-1.87%+42.87%+67.17% 63.77B
-1.14%+2.28%+12.43%+72.21% 56.37B
+0.75%+2.33%+20.47%+103.00% 54.62B
-2.81%-4.31%+23.50%+48.51% 44.06B
-0.33%-1.93%+19.28%+104.26% 42.11B
+0.55%+2.31%+225.14%+840.10% 41B
-3.02%+27.80%+103.16%+91.89% 34.92B
+1.22%-1.44%+14.57%+47.05% 32.82B
+0.89%+20.55%-40.62%+350.50% 24.7B
Average -0.48%+7.54%+46.75%+191.63% 43.82B
Weighted average by Cap. -0.55%+5.44%+47.44%+173.36%

Financials

2024 2025
Net sales - -
Net income 1.04M 1.27M 1.13M 946K 1.77M 120M 1.8M 12.45M 5M 63.28M 4.76M 4.65M 200M -653K -792K -710K -591K -1.11M -75.23M -1.13M -7.78M -3.12M -39.57M -2.97M -2.91M -125M
Net Debt -6.75M -8.2M -7.34M -6.12M -11.44M -778M -11.65M -80.53M -32.33M -409M -30.76M -30.11M -1.29B -5.91M -7.17M -6.42M -5.35M -10M -681M -10.19M -70.43M -28.27M -358M -26.9M -26.33M -1.13B
Logo ARPIDA
EvoNext Holdings Ltd, previously Evolva Holding Ltd, is a Switzerland-based Company operating as a researcher for biotechnology. The Company develops and commercializes nature-based ingredients. The ingredients, produced by the Company, can be employed in, but not limited to, flavorings fragrancies, health ingredients, health protection and other various sectors. The objectives of the Company are as follows: develop technology platforms - combines biology with technology to produce nature-based ingredients; provide technology services- provides tailored services to clients across industries. The Company is focused on developing and increasing the return and effectiveness of the production of numerous ingredients within their portfolio.
Employees
-